Posters
Read research from Cogstate scientists as presented at industry conferences.
Remote assessment of cognition with the unsupervised version of the Cogstate Brief Battery: Association of composite endpoints with Alzheimer’s disease biomarkers
ISCTM 2025
With recent approval of disease modifying therapies for early symptomatic Alzheimer’s disease (AD), interest has grown in secondary prevention trials (defined as the presence of AD pathology in clinically normal individuals). However, it takes screening massive numbers of people to identify cognitively normal people with biomarker evidence of AD. Cognitive assessment can be made efficient through use of internet based registries, which can be linked to clinical trials for potential therapies, but understanding of the relationship between performance on assessments and AD biomarkers is needed. The Cogstate Brief Battery (CBB), a compilation of 4 cognitive tests, has been optimized for unsupervised, remote use in registries. To determine the utility of validity of data collected from remote administration of the CBB, data from cognitively unimpaired (CU) middle aged adults with various AD risk factors, enrolled in a registry, were investigated for relationships with in-clinic performance on standardized neuropsychological assessments and with AD biomarkers obtained from cerebral spinal fluid (CSF) sampling.
View PosterAcceptability and Validity of the Smartphone-Administered Version of the Cogstate Brief Battery in Adult Participants of the Healthy Brain Project
ISCTM 2025
This poster presents findings from a study examining the acceptability and validity of the smartphone-administered version of the Cogstate Brief Battery (CBB) in cognitively unimpaired middle-aged and older adults. Unsupervised, remote administration of cognitive tests may lead to more accessible and accurate representations of cognitive function in everyday life compared to in-clinic neuropsychological assessments.
View PosterAcceptability and validity of a smartphone-administered word list learning test (LILA) in cognitively unimpaired adults
The Healthy Brain Project
This poster presents findings from a study examining the acceptability of a remote self-administered version of the International Shopping List Test (ISLT), known as LILA, in cognitively unimpaired middle-aged and older adults. The ISLT is a rater-administered verbal list learning test used to detect memory dysfunction in early Alzheimer’s disease (AD). The validity of LILA was assessed by analyzing learning curves and exploring relationships between key demographic factors, such as age, sex, education, and mood, that are known to influence cognitive performance.
View PosterCentral Monitoring and Data Quality Assurance: Identifying and Correcting Errors in Category and Letter Fluency Tests in CNS Clinical Trials
ISCTM 2024
This poster highlights the presence of scoring errors in both CFT and LFT administrations, emphasizing a crucial area for quality improvement. A significant portion of these reviews are impacted by errors, potentially affecting the validity and reliability of the tests. Contributing factors include the complexity of the tests, inconsistent administration practices, and human error. Addressing these issues is essential for improving the accuracy and consistency of fluency assessments, ultimately leading to more reliable outcomes in both clinical and research environments.
View PosterTAK-861 improves cognitive impairments in patients with narcolepsy type 1
ESRS 2024
In this phase 2 trial, 8 weeks of treatment with TAK-861 demonstrated significant improvements in sustained attention (PVT), memory (CPAL), and executive function (ONB, iDSST-s) in individuals with narcolepsy type 1 (NT1). Notably, the benefits in sustained attention were consistent both 1 and 7 hours post-morning dose. These findings highlight the potential of OX2R agonists like TAK-861 to address cognitive impairments associated with NT1, offering a promising therapeutic approach.
View PosterChange in sustained attention, global function, disease severity, activities of daily living and quality of life, in narcolepsy type 1
ESRS 2024
In this phase 2 clinical trial, 8 weeks of treatment led to significant improvements in sustained attention among patients with narcolepsy type 1 (NT1). Cross-sectional analysis at week 8 showed that impairments in sustained attention were associated with greater disease severity and reduced ability to perform daily activities. Improvements in sustained attention were linked to meaningful enhancements in global function, quality of life, and daily living activities. These findings suggest that sustained attention not only reflects NT1 disease severity but that improvements in attention correlate with better daily functioning.
View PosterDissociation of symptoms of excessive daytime sleepiness and attentional impairment in narcolepsy type 1
ESRS 2024
In this phase 2 clinical trial, 8 weeks of treatment with TAK-861 led to significant improvements in sustained attention for individuals with narcolepsy type 1 (NT1). Interestingly, baseline assessments showed that sustained attention was weakly to moderately associated with subjective sleepiness (measured by the Epworth Sleepiness Scale, ESS). Notably, 64.1–65.0% of the treatment effect on attention was directly attributable to TAK-861 itself, independent of improvements in sleepiness or the Maintenance of Wakefulness Test (MWT), suggesting that attentional impairments in NT1 may be dissociated from excessive daytime sleepiness (EDS). These findings indicate that TAK-861 may target both attentional impairments and EDS, likely addressing the underlying pathophysiology of NT1.
View PosterCentral monitoring of rater performance and characteristics of efficacy assessments in the TRAILBLAZER-ALZ 2 study
Presented at ADPD 2024
TRAILBLAZER-ALZ 2 (NCT04437511) is a phase 3 study that evaluated the safety and efficacy of donanemab in individuals with early symptomatic Alzheimer’s disease (AD) with confirmed amyloid presence and specified tau levels. Although most clinical trials […]
View PosterInvestigating Cognitive Practice Effects in Schizophrenia Using Repeated Assessment at Short Retest Intervals Prior to Randomization in a Clinical Trial
Presented at ISCTM 2024
In clinical trials of schizophrenia, improvement in cognition in both placebo and treatment arms is common. Such improvementmay impact the ability of clinical trials to identify any cognitive benefits of new pharmacotherapies (Keefe et al., 2011). […]
View PosterRemote Assessment of Cognition with the Unsupervised Version of the Cogstate Brief Battery: Association of Composite Endpoints with Alzheimer’s Disease Biomarkers
Presented at ADPD 2024
In people at risk of Alzheimer’s disease (AD), access to cognitive assessment can be increased through application of internet-based registries. While cognitive data collected remotely from registries provides only limited information to support clinical decision making, it can be linked to specialist management clinics which allow for analyses and more comprehensive follow-up. The Cogstate Brief Battery (CBB) has been optimized for unsupervised and remote use in registries with CBB outcomes shown to be sensitive to dementia risk factors such as carriage of the Apoe4 allele, higher levels of cerebral vascular risk factors, and sleep disorders. Furthermore, new analyses of data from the CBB has indicated that multiple composite scores are sensitive to AD related cognitive impairment.
View Poster